PHARMING ANNOUNCES POSITIVE PHASE II TOPLINE DATA FOR LENIOLISIB IN PIDS WITH IMMUNE DYSREGULATION ACCEPTED AS LATE-BREAKING ABSTRACT AT ESID 2026

Reuters · 1d ago

Please log in to view news